For Research Use Only

 

Summary:

The BNP Fragment (nt-proBNP 8-29) ELISA is an enzyme imunoassay for the quantitative determination of nt-proBNP (8-29) in Serum or Plasma. The mature form of brain natriuretic peptide (BNP) is formed from the BNP (1-108) precursor and is secreted predominantly by the cardiac ventricles. Circulating forms of BNP include BNP-32 (77-108), a high molecular weight BNP which has not been well characterizedand and the nt-proBNP (1-76). The BNP fragment is typically measured as a proxy for BNP because of its longer half-life. Recent research suggests that natriuretic peptides are important protectors against fluid overload and high blood pressure. BNP has also been implicated as a valuable marker in assessing cardiac risk.

Literature References:

Clerico A, DelRy S, Giannessi D, Trianni G, Rizza A, Botto N, and Biagini A. Evaluation and comparison of commercial immunoassay methods for the determination of N-terminal proANP in plasma and atrial cardiac tissue. J of Clin Ligand Assay. 2001; 24:112-118.

Clerico A, and Emdin M. Diagnostic Accuracy and Prognostic Relevance of the Measurement of Cardiac Natriuretic Peptides: A Review. Clinical Chemistry. 2004; 50:1 33-50.

Hammerer-Lercher A, Puschendorf B and Mair J. Cardiac Natriuretic Peptides: New Laboratory Parameters in Heart Failure Patients. Clin Lab. 2001; 47:265-277.

Globits S, Frank H, Pacher B, Huelsmann M, and Pacher M. Atrial Natriuretic Peptide Release Is More Dependent on Atrial Filling Volume Than on Filling Pressure in Chronic Congestive Heart Failure Am Heart J. 1998 Apr;135(4):592-7.

Müller MM, and Griesmacher A. New Trends in Classification, Monitoring and Management of Cardiovascular Diseases. Berichte der ÖGKC. 2002; Jg. 25, 56 – 62.

Troughton RW, Frampton CM, Yandle TG, Espiner EA, Nicholls MG, and Richards AM. Treatment of heart failure guided by plasma aminoterminal brain natriuretic peptide (N-BNP) concentrations. THE LANCET. 2002; Vol 355, 1126-1130.

Mueller T, Gegenhuber A, Poelz W, Haltmayer W. Comparison of the Biomedica NT-proBNP Enzyme Immunoassay and the Roche NT-proBNP Chemiluminescence Immunoassay: Implications for the Prediction of Symptomatic and Asymptomatic Structural Heart Disease. Clinical Chemistry. 2003; 49, No. 6, 976-979.

Stanek B, Frey B, Hulsmann M, Berger R, Sturm B, Strametz-Juranek J, Bergler-Klein J, Moser P, Bojic A, Hartter E, Pacher R. Prognostic evaluation of neurohumoral plasma levels before and during beta-blocker therapy in advanced left ventricular dysfunction. J Am Coll Cardiol. 2001 Aug; 38(2):436-42.